

DAFTAR PUSTAKA

- Adwardahana J., Wreksoatmodjo BR. 2023. Efek Neurologis Hipokalemia dan Hiperkalemia. *CDK-321*. 50(10) : 555-561.
- Alexopoulou, Alexandra. 2008. Adverse Drug Reaction as a cause of Hospital Admissions: A 6-Month Experience in a Single Center in Greece. *European Journal of Internal Medicine*, 19:505–510.
- Alomar MJ. 2014. Factors affecting the development of adverse drug reactions (Review article). *Saudi Pharm J*. 2 :83-94.
- Amin S., Shah S., Desai M., Shah A., Maheriya KM. 2018. An analysis of adverse drug reactions in extremes of age group at tertiary care teaching hospital. *Perspect Clin Res*. 9(2):70-75.
- Andrade PHS, Santos ADS, Souza CAS, Lobo IMF, da Silva WB. 2017. Risk factors for adverse drug reactions in pediatric inpatients: a systematic review. *Ther Adv Drug Saf*. 6:199-210.
- Bakaki PM., Horace A., Dawson N., Winterstein A., Waldron J., Staley J., Pestana Knight EM., Meropol SB., Liu R., et al. 2018. Defining pediatric polypharmacy: A scoping review. *PLoS One*. 13(11): 1-23.
- Balai Pengawasan Obat dan Makanan Republik Indonesia. 2019. Farmakovigilans (Keamanan Obat): Panduan Deteksi Dan Pelaporan Efek Samping Obat Untuk Tenaga Kesehatan. Jakarta: BPOM RI.
- Batchelor HK, Marriott JF. 2015. Paediatric pharmacokinetics: key considerations. *Br J Clin Pharmacol*. 79 :395-404.
- Bazzano, ATF., Mangione-Smith, R., Schonlau, M., Suttrop, MJ., Brook, RH. 2009. Off-label prescribing to children in the United States outpatient setting. *Acad Pediatr*; 9(2): 81-88.
- Bellis JR, Kirkham JJ, Thiesen S, Conroy EJ, Bracken LE, Mannix HL, Bird KA, Duncan JC, Peak M, Turner MA, Smyth RL, Nunn AJ, Pirmohamed M. 2013. Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. *BMC Med*, 11: 3-8.
- Bellis JR., Kirkham JJ., Nunn AJ., Pirmohamed M. 2014. Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital. *Br J Clin Pharmacol*. 77(3):545-553.
- BNF for Children. 2020. *BNF for Children September 2020-2021*. BMJ. Group and The Royal Pharmaceutical Society : London

- Czaja AS., Reiter PD., Schultz ML., Valuck RJ. 2015. Patterns of Off-Label Prescribing in the Pediatric Intensive Care Unit and Prioritizing Future Research. *J Pediatr Pharmacol Ther.* 20 (3):186-96.
- Carnovale C, Conti V, Perrone V, Antoniazzi S, Pozzi M, Merlino L, et al. 2013. Paediatric drug use with focus on off-label prescriptions in Lombardy and implications for therapeutic approaches. *Eur J Pediatr* 2013; 172(12): 1679-85.
- Chalumeau, M., Tréluyer, JM., Salanave, B., Assathiany, R., Chéron, G., Crocheton, N et al. 2000. Off label and unlicensed drug use among French office based paediatricians. *Arch Dis Child*; 83(6): 502-505.
- Danes, I., Agusti, A., Vallano, A., Alerany, C., Martinez, J., Bosch, A. J., Bonafont, X. 2014. Outcomes of off-label drug uses in hospitals: a multicentric prospective study. *EUR J Clin Pharmacol.* 70 :1386-1393.
- Departemen Kesehatan RI. 2009. *Pedoman Pelayanan Kefarmasian Untuk Pasien Pediatri*. Depkes : Jakarta.
- DiPiro J.T., Wells B.G., Schwinghammer T.L., DiPiro C. V. 2015. *Pharmacotherapy Handbook, Ninth Edit.* McGraw-Hill Education Companies : Inggris.
- Faubion Jr., Zein, NN. 1998. Gastroesophageal reflux in infants and children. *Mayo Clin Proc* ;73(2):166-73. .
- Feinstein J., Dai D., Zhong W., Freedman J., Feudtner C. 2015. Potential Drug-Drug Interactions in Infant, Child, and Adolescent Patients in Children's Hospitals. *Pediatrics.* 135(1):99–108.
- Fleischhacker WW., Uchida H. 2014. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. *Int J Neuropsychopharmacol.* 17(7):1083–93.
- Gallego JA., Nielsen J., Hert M De., Kane JM., Correll CU. 2013. Safety and Tolerability of Antipsychotic Polypharmacy. *Expert Opin Drug Saf.* 11(4):527–42
- Gnjidic D., Hilmer SN., Blyth FM., Naganathan V., Waite L., Seibel MJ et al. 2012. Polypharmacy cutoff and outcomes: Five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. *J Clin Epidemiol.* 65(9):989–95
- Hainsworth J., Harvey W., Pendergrass K., et al. 1991. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. *J Clin Oncol.* 9(5):721–728.

- Hakamifard A., Aria A., Momenzadeh M. 2022. Severe Ondansetron-associated Hypokalemia in a Patient Diagnosed with Aspiration Pneumonia. *J Res Pharm Pract.* 11(2) : 87-90.
- Hoon D, Taylor MT, Kapadia P, Gerhard T, Brian L. Strom BL, *et al.* 2019. Trends in off-label drug use in ambulatory settings: 2006-2015. *Pediatrics.* 144 : 1-19.
- Horen B, Montastruc JL, Lapeyre-Mestre M. 2002. Adverse drug reactions and off-label drug use in paediatric outpatients. *Br J Clin Pharmacol.* 54 :665-670.
- Imran, S., Thabab, MM., Azharudeen, M., Ramesh, A., Bobby, Z., Negi VS. 2021. Liver Abnormalities in Systemic Lupus Erythematosus: A Prospective Observational Study. *Cureus.* 13(6) : 2-8.
- Janelins MC., Tejani M., Kamen C., Peoples A., Mustian KM., Morrow GR., 2013. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. *Expert Opin Pharmacother.* 14(6): 757–766
- Jørgensen H., Knigge U., Kjaer A., Warberg J. 2002. Serotonergic involvement in stress-induced vasopressin and oxytocin secretion. *Eur J Endocrinol.* 147(6) :815-824
- Kaguelidou F., Beau-Salinas F., Jonville-Bera AP., Jacqz-Aigrain E. 2016. Neonatal adverse drug reactions: an analysis of reports to the French pharmacovigilance database. *Br J Clin Pharmacol.* 82(4):1058-68.
- Khan RB. 2002. Migraine-type headaches in children receiving chemotherapy and ondansetron. *J Child Neurol.* 17(11) : 857-858.
- Khan, Z., Muhammad, K., Karatas, Y. *et al.* 2020. Pharmacovigilance and incidence of adverse drug reactions in hospitalized pediatric patients: a mini systematic review. *Egypt Pediatric Association Gaz* 68. 24 : 11-17.
- Khan, LM., Al-Harthi, SE., Saadah, OI. 2013. Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR. *Saudi Pharmaceutical Journal*, 21(3), 261–266.
- Koda-Kimble MA, Young LY, Alldredge B, Corelli RL, Guglielmo BJ, Kradjan WA, Williams BR. 2013. *Applied Therapeutics: The Clinical Use of Drugs (10th Edition)*. Lippincott Williams & Wilkins : USA.
- Landwehr C. *et al.* 2019. Cross-sectional survei *off-label* and unlicensed prescribing for inpatients at a pediatric teaching hospital in western Australia. *Plos One.* 14(1) : 3-8.
- Lee JH., Byon HJ., Choi S., Jang Ye., Kim EH., Kim JT., Kim HS. 2018. Safety and Efficacy of Off-label and Unlicensed Medicines in Children. *J Korean Med Sci.* 33(37): 1-10.

- Lewandowski MJ., Chapman SA. 2008. Ondansetron-induced aminotransferase level elevation: case report and review of the literature. *Pharmacotherapy*. 28(12):1542-1546.
- Lexicomp. 2023. *Domperidon*. Diakses 10 Maret 2024 dari https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668235?cesid
- Lexicomp.2023. Ondansetron (*Pediatric and Neonatal Lexi Drugs*). Diakses 10 Maret 2024 dari https://online.lexi.com/lco/action/doc/retrieve/docid/pdh_f/130191?cesid=7VQhweRETB&searchUrl
- López-Valverde L, Domènech È, Roguera M, Gich I, Farré M, Rodrigo C, Montané E. 2021. Spontaneous Reporting of Adverse Drug Reactions in a Pediatric Population in a Tertiary Hospital. *J Clin Med*. 10 : 1-15
- Lu H, Rosenbaum S. 2014. Developmental pharmacokinetics in pediatric populations. *J Pediatr Pharmacol Ther*. 19: 262-276.
- M Saiyed., Tarachand, Lalwani., Devang Rana. 2014. "Off-Label Medicine Use in Pediatric Inpatients: A Prospective Observational Study at a Tertiary Care Hospital in India", *International Journal of Pediatrics*. Volume 14. Article ID 415815 : 1-6
- Mangoni AA, Jackson SH. 2004. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. *Br J Clin Pharmacol*. 57: 6-14.
- Matthew., Lightdale JR. 2018. Vomiting in Children. *Pediatr Rev*. 39:342-358.
- Masnoon N., Shakib S., Kalisch-Ellett L., Caughey GE. 2017.What is polypharmacy? A systematic review of definitions. *BMC Geriatr*. 230 (17) :1–10.
- Meng M, Zhou Q, Lei W, Tian M, Wang P, Liu Y, Sun Y, Chen Y, Li Q. Recommendations on Off-Label Drug Use in Pediatric Guidelines. *Front Pharmacol*. 13: 1-12.
- Morales-Ríos O., Jasso-Gutiérrez L., Reyes-López A., Garduño-Espinosa J., Muñoz-Hernández O. 2018. Potential drug-drug interactions and their risk factors in pediatric patients admitted to the emergency department of a tertiary care hospital in Mexico. *PLoS One*. 13(1): 1-14.
- Morris AD., Chen J., Lau E., Poh J. 2016. Domperidone-Associated QT Interval Prolongation in Non-oncologic Pediatric Patients: A Review of the Literature. *Can J Hosp Pharm*. 69(3):224-30.
- Mustian KM., Devine K., Ryan JL., Janelins MC., Sprod LK., Peppone LJ., et al. 2011. Treatment of nausea and vomiting during chemotherapy. *US Oncol Hematol*. 7(2) : 91-97.

- National Institute of Diabetes and Digestive and Kidney Disease. 2012. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury : Serotonin 5-HT₃ Receptor Antagonists. *Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Disease*. PMID: 31643518.
- Oh JH, Kwon JG, Jung HK, Tae CH, Song KH, Kang SJ, Kim SE, Jung K. et al. 2020. Functional Dyspepsia Research Group and Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. *Clinical Practice Guidelines for Functional Dyspepsia in Korea. J Neurogastroenterol Motil* ; 26(1) :29-50.
- Patel A., Mittal S., Manchanda S., Puliye JM. 2011. Ondansetron-induced dystonia, hypoglycemia, and seizures in a child. *Ann Pharmacother*. 45(1): 1-3.
- Plotsky PM., Bruhn TO., Vale W. 1985. Hypophysiotropic regulation of adrenocorticotropin secretion in response to insulin-induced hypoglycemia. *Endocrinology*. 117(1) : 323-329.
- Posthumus AAG, Alingh CCW, Zwaan CCM, et al. 2012. Adverse drug reaction-related admissions in paediatrics, a prospective single-centre study. *BMJ Open*. 2: 1-6.
- Priyadharsini R, Surendiran A, Adithan C, Sreenivasan S, Sahoo FK. 2011. A study of adverse drug reactions in pediatric patients. *J Pharmacol Pharmacother*, 2 : 277-280.
- Putri, Nurul I., Bachtiar, A., Andrajati, R. 2021. Pengaruh Penggunaan Obat *On-Label* dan *off-label* dengan Munculnya Reaksi Obat Tidak Dikehendaki pada Pasien Pediatrik. *Pharmaceutical Journal of Indonesia*. 18 : 138 - 149.
- Ranganathan S Sri, Mayurathan K, Fernandopulle R. 2010. A survey on antiemetics prescribed for children in some selected districts of Sri Lanka. *Sri Lanka Journal of Child Health*. 3: 93-97.
- Rhew K., Han N., Oh JM. 2019. Impact of Safety Warning on Domperidone Prescribing for Geriatric Patients in South Korea: Analysis of National Insurance Claim Data. *Int J Environ Res Public Health*. 16(16):1-9.
- Romano, C., Dipasquale, V., Scarpignato, C., 2019. Antiemetic Drug Use in Children: What the Clinician Needs to Know. *Journal of Pediatric Gastroenterology and Nutrition*. 68 : 466-471.
- Ruggiero A., Rizzo D., Catalano M., Coccia P., Triarico S., Attinà G., 2018. Acute chemotherapy-induced nausea and vomiting in children with cancer: Still waiting for a common consensus on treatment. *J Int Med Res*. 46(6):2149-2156.

- Rusli, 2018. *Bahan Ajar Farmasi: Farmasi Klinik Edisi 2018*. Kementerian Kesehatan Republik Indonesia : Makassar.
- Saiyed MM, Lalwani T, Rana D. 2015. Is off-label use a risk factor for adverse drug reactions in pediatric patients? A prospective study in an Indian tertiary care hospital. *Int J Risk Saf Med*. **27**:45-53.
- Santos DB., Clavenna A., Bonati M., Coelho HL. 2008. Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil. *Eur J Clin Pharmacol*. **64** (11): 1111-1118.
- Shann, Frank. 2017. *Drug Doses seventh edition*. Departemen of Paediatrics University of Meoulbourne: Australia
- Shanshal, Aysha M., Hussain, Saad A. 2021. off-label Prescribing Practice in Pediatric Settings: Pros and Cons. *Sys Rev Pharm*. **12**:1267-1275
- Simbolon, PDH., Nafianti, S., Sianturi, P., Lubis, B., Lelo, A. 2018. The addition of omeprazole to ondansetron for treating chemotherapy-induced nausea and vomiting in pediatric cancer patients. *Paediatrica Indonesiana*. **58**(1) : 42-47.
- Sobari, V. 2018, Identifikasi Penggunaan Obat Off-Label Indikasi Pada Pasien Pediatri Rawat Inap Di Rumah Sakit Umum Pusat Dr. Sardjito D.I. Yogyakarta Periode Tahun 2016, *Tesis*, MSc, Fakultas Farmasi, Universitas Muhammadiyah Yogyakarta.
- Spiller R. 2002 Serotonergic modulating drugs for functional gastrointestinal diseases. *Br J Clin Pharmacol*. **54**(1) :11-20.
- Sumida, K., Yamagata, K, Kovesdy CP. 2019.Constipation in CKD. *Kidney Int Rep*. **5**(2):121-134.
- Tai D, Dick P, To T, Wright JG. 2006. Development of pediatric comorbidity prediction model. *Arch Pediatr Adolesc Med*. **160**:293–9.
- Theal JJ., Toosi MN., Girlan L., Heslegrave RJ., Huet PM., Burak KW., Swain M., Tomlinson GA., Heathcote EJ. 2005. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. *Hepatology*. **41**(6) : 1305-1312.
- Thome-Souza S., Freitas A., Fiore LA., Valente KD.2003. Lamotrigine and valproate: Efficacy of co-administration in a pediatric population. *Pediatr Neurol*. **28**(5):360–4.
- Torres-Espíndola LM., Demetrio-Ríos J., Carmona-Aparicio L., Galván-Díaz C., Pérez-García M., Chávez-Pacheco JL., Granados-Montiel J., Torres-Ramírez de Arellano I *et al*. 2019. Comorbidity Index as a Predictor of Mortality in Pediatric Patients With Solid Tumors. *Front Pediatr*. **7**(48) : 1-7

- Uptodate. 2023. Gastrointestinal manifestations of systemic lupus erythematosus. diakses 20 Maret 2024 dari [https:// www.uptodate.com/contents/gastrointestinal-manifestations-of-systemic-lupus erythematosus?search](https://www.uptodate.com/contents/gastrointestinal-manifestations-of-systemic-lupus-erythematosus?search)
- Van der Zanden TM., Mooij MG., Vet NJ., Neubert A., Rascher W., Lagler FB., Male C., Grytli H., Halvorsen T., de Hoog M., de Wildt SN. 2021. Benefit-Risk Assessment of Off-Label Drug Use in Children: The Bravo Framework. *Clin Pharmacol Ther.* 10(4) : 952-965.
- Victor, A., 2007, Penggunaan Obat *off-label* Pada Pasien Anak. *Bul. Penel. Kesehatan.* 35 : 90-94.
- Viechtbauer, W., Smits, L., Kotz, D., Budé, L., Spigt, M., Serroyen, J., & Crutzen, R. 2015. A simple formula for the calculation of sample size in pilot studies. *Journal of Clinical Epidemiology.* 68 : 1375-1379.
- Wiffen P, Gill M, Edwards J, Moore A., 2002. Adverse drug reactions in hospital patients. A systematic review of the prospective and retrospective studies, *Bandolier Extra.* 1–16.
- World Health Organization (WHO). 2018. *Standards for improving quality of care for children and young adolescents in health facilities.* WHO : Geneva
- Zanon D, Gallelli L, Rovere F. *et al.* 2013. Off-Label prescribing patterns of antiemetics in children: A multicenter study in Italy. *Eur J Pediatr.* 172:361–367.